Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription - Scorecard - MDSpire
Advertisement
Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription
Clinical Scorecard: Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription
At a Glance
Category
Detail
Condition
Empirical treatment of suspected drug-resistant Gram-positive bacterial infections, particularly in low MRSA incidence areas.
Key Mechanisms
Target Population
Care Setting
Key Highlights
Overuse of vancomycin for empirical treatment is common, with significant rates of inappropriate prescriptions.
Only 8.3% to 9.6% of S. aureus isolates in Thailand are MRSA, questioning the justification for empirical vancomycin use.
A significant proportion of patients receiving empirical vancomycin do not require it as definitive therapy.
Guideline-Based Recommendations
Diagnosis
Initiate vancomycin if there are signs of inflamed exit site of CVC, suspicion of skin and soft tissue infection, pneumonia, or haemodynamic instability.
In febrile neutropenic patients, initiate if there are signs of infection or high risk based on clinical judgment.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
532 pediatric patients treated with empirical vancomycin
Only a small percentage required vancomycin as definitive therapy, indicating potential overprescription.
Clinical Best Practices
Adhere to guidelines for empirical vancomycin use based on local MRSA prevalence.
Evaluate the necessity of vancomycin in febrile neutropenic patients and those with suspected bacterial meningitis.
Monitor for adverse effects and therapeutic drug levels in patients receiving vancomycin.
